"id","rationale","name","description","label","uuid:ID","instanceType"
"StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","The main design for the study","","d9497a2e-6bcf-4707-841a-29ba3f6d6030","StudyDesign"
